Medics Autonomously Stopping Hemorrhage (MASH)

This DARPA MASH program seeks innovative solutions for autonomously stopping hemorrhaging in trauma casualties. The 36-month program (24-month Phase I, 12-month Phase II option) requires development of a robotic system capable of detecting, localizing, and treating bleeding, culminating in Phase I and II IV&V tests. Critical requirements include a comprehensive Techno-Economic Assessment (TEA) evaluating technical feasibility and economic viability, including regulatory and commercialization pathways, and demonstrating alignment with clinical and market needs. The program emphasizes a phased approach with specific milestones, deliverables (including TEA outlines and final reports), and metrics for evaluating progress. Phase I focuses on independent system capabilities (detection, localization, treatment), while Phase II integrates these into an autonomous hemostasis workflow, culminating in a field-ready portable system design (paper study only). Proposers must detail their technical approach, including robotic hardware, algorithms, training methodology, and system integration, along with risk mitigation strategies and a plan for obtaining sufficient training data. Successful proposals will demonstrate the team's technical ability, provide a detailed cost breakdown, and outline a data archiving and sharing strategy. The program will involve multiple meetings, including a Phase I Preliminary Design Review (PDR) and a Phase II Critical Design Review (CDR).

Notice ID

6d826add665048888c9317b598e61991

Solicitation Number

DARPA-PS-25-34

NAICS Code

541714

Classification Code

AC12